{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:54:49Z","timestamp":1791942889296,"version":"4.3.4"},"reference-count":268,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ejmech.2019.01.045","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T18:15:19Z","timestamp":1548699319000},"page":"10-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Toward the discovery and development of effective modulators of \u03b1-synuclein amyloid aggregation"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-4790","authenticated-orcid":false,"given":"Valentina","family":"Oliveri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1021\/cr040410w","article-title":"Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis)","volume":"106","author":"Gaggelli","year":"2006","journal-title":"Chem. Rev."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2019.01.045_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11010-010-0563-x","article-title":"Metals, oxidative stress and neurodegenerative disorders","volume":"345","author":"Jomova","year":"2010","journal-title":"Mol. Cell. Biochem."},{"issue":"9","key":"10.1016\/j.ejmech.2019.01.045_bib3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nn0901-859","article-title":"Protofibrils, the unifying toxic molecule of neurodegenerative disorders?","volume":"4","author":"Haass","year":"2001","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.archger.2007.03.003","article-title":"Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment","volume":"46","author":"Borroni","year":"2008","journal-title":"Arch. Gerontol. Geriatr."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100 years of Lewy pathology","volume":"9","author":"Goedert","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"5999","key":"10.1016\/j.ejmech.2019.01.045_bib7","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"\u03b1-Synuclein promotes SNARE-complex assembly in\u00a0vivo and in\u00a0vitro","volume":"329","author":"Burr\u00e9","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JPD-150642","article-title":"The synaptic function of \u03b1-synuclein","volume":"5","author":"Burr\u00e9","year":"2015","journal-title":"J.\u00a0Parkinson's Dis."},{"key":"10.1016\/j.ejmech.2019.01.045_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jchemneu.2016.06.001","article-title":"Alpha-synuclein modulates dopamine neurotransmission","volume":"83","author":"Butler","year":"2017","journal-title":"J.\u00a0Chem. Neuroanat."},{"issue":"7","key":"10.1016\/j.ejmech.2019.01.045_bib11","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.bpj.2010.06.035","article-title":"The N-terminus of the intrinsically disordered protein \u03b1-synuclein triggers membrane binding and helix folding","volume":"99","author":"Bartels","year":"2010","journal-title":"Biophys. J."},{"issue":"16","key":"10.1016\/j.ejmech.2019.01.045_bib12","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1074\/jbc.273.16.9443","article-title":"Stabilization of \u03b1-synuclein secondary structure upon binding to synthetic membranes","volume":"273","author":"Davidson","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1096\/fj.03-0338rev","article-title":"\u03b1-Synuclein and Parkinson's disease","volume":"18","author":"Recchia","year":"2004","journal-title":"FASEB J."},{"issue":"12","key":"10.1016\/j.ejmech.2019.01.045_bib14","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1212\/01.wnl.0000254458.17630.c5","article-title":"Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication","volume":"68","author":"Fuchs","year":"2007","journal-title":"Neurology"},{"issue":"5646","key":"10.1016\/j.ejmech.2019.01.045_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/science.1090278","article-title":"\u03b1-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"issue":"9440","key":"10.1016\/j.ejmech.2019.01.045_bib16","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"\u03b1-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2019.01.045_bib17","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson's disease","volume":"41","author":"Simon-Sanchez","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2019.01.045_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2012.06.025","article-title":"Gene\u2013environment interactions in Parkinson's disease: specific evidence in humans and mammalian models","volume":"57","author":"Cannon","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1750-3639.2011.00545.x","article-title":"Autophagy in dementias","volume":"22","author":"Kragh","year":"2012","journal-title":"Brain Pathol."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/biom5020435","article-title":"The interplay between alpha-synuclein clearance and spreading","volume":"5","author":"Lopes da Fonseca","year":"2015","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib21","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1074\/jbc.C113.538249","article-title":"Evidence of native \u03b1-synuclein conformers in the human brain","volume":"289","author":"Gould","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0022-2836(02)00735-0","article-title":"\u03b1-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils","volume":"322","author":"Lashuel","year":"2002","journal-title":"J.\u00a0Mol. Biol."},{"issue":"39","key":"10.1016\/j.ejmech.2019.01.045_bib23","doi-asserted-by":"crossref","first-page":"37530","DOI":"10.1074\/jbc.M305266200","article-title":"Structural organization of \u03b1-synuclein fibrils studied by site-directed spin labeling","volume":"278","author":"Der-Sarkissian","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"issue":"25","key":"10.1016\/j.ejmech.2019.01.045_bib24","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.1073\/pnas.0712179105","article-title":"The fold of \u03b1-synuclein fibrils","volume":"105","author":"Vilar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2019.01.045_bib25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ejmech.2016.01.044","article-title":"Coupling of the non-amyloid-component (NAC) domain and the KTK (E\/Q) GV repeats stabilize the \u03b1-synuclein fibrils","volume":"121","author":"Xu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"6369","key":"10.1016\/j.ejmech.2019.01.045_bib26","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.aan6160","article-title":"Structural basis of membrane disruption and cellular toxicity by \u03b1-synuclein oligomers","volume":"358","author":"Fusco","year":"2017","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib27","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In\u00a0vivo demonstration that \u03b1-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib28","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","article-title":"Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein","volume":"149","author":"Cremades","year":"2012","journal-title":"Cell"},{"issue":"34","key":"10.1016\/j.ejmech.2019.01.045_bib29","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","article-title":"Different species of \u03b1-synuclein oligomers induce calcium influx and seeding","volume":"27","author":"Danzer","year":"2007","journal-title":"J.\u00a0Neurosci."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib30","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/biom5020282","article-title":"Seeking a mechanism for the toxicity of oligomeric \u03b1-synuclein","volume":"5","author":"Roberts","year":"2015","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.25373","article-title":"Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?","volume":"28","author":"Olanow","year":"2013","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.3457","article-title":"Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases","volume":"20","author":"Guo","year":"2014","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.ejmech.2019.01.045_bib33","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.1073\/pnas.1315346111","article-title":"Solution conditions determine the relative importance of nucleation and growth processes in \u03b1-synuclein aggregation","volume":"111","author":"Buell","year":"2014","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2019.01.045_bib34","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1012336107","article-title":"Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation","author":"Anderson","year":"2010","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib35","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1021\/bi011711s","article-title":"Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from \u03b1-synuclein in\u00a0vitro","volume":"41","author":"Cohlberg","year":"2002","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0167-4838(00)00106-0","article-title":"Eosin interaction of \u03b1-synuclein leading to protein self-oligomerization","volume":"1481","author":"Shin","year":"2000","journal-title":"Biochim. Biophys. Acta Protein Struct. Mol. Enzymol."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib37","first-page":"295","article-title":"Self-oligomerization and protein aggregation of \u03b1-synuclein in the presence of Coomassie Brilliant Blue","volume":"268","author":"Lee","year":"2001","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-5793(01)02597-2","article-title":"Pesticides directly accelerate the rate of \u03b1-synuclein fibril formation: a possible factor in Parkinson's disease","volume":"500","author":"Uversky","year":"2001","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.toxlet.2014.11.029","article-title":"The molecular mechanism of rotenone-induced \u03b1-synuclein aggregation: emphasizing the role of the calcium\/GSK3\u03b2 pathway","volume":"233","author":"Yuan","year":"2015","journal-title":"Toxicol. Lett."},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib40","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1074\/jbc.M208249200","article-title":"Cellular polyamines promote the aggregation of \u03b1-synuclein","volume":"278","author":"Antony","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib41","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/sj.emboj.7600211","article-title":"NMR of \u03b1-synuclein\u2013polyamine complexes elucidates the mechanism and kinetics of induced aggregation","volume":"23","author":"Fern\u00e1ndez","year":"2004","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib42","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1471-4159.2006.04017.x","article-title":"Effects of the cholesterol-lowering compound methyl-\u03b2-cyclodextrin in models of \u03b1-synucleinopathy","volume":"98","author":"Bar-On","year":"2006","journal-title":"J.\u00a0Neurochem."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.expneurol.2009.11.015","article-title":"Lovastatin ameliorates \u03b1-synuclein accumulation and oxidation in transgenic mouse models of \u03b1-synucleinopathies","volume":"221","author":"Koob","year":"2010","journal-title":"Exp. Neurol."},{"issue":"17","key":"10.1016\/j.ejmech.2019.01.045_bib44","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/asia.201600824","article-title":"Cyclodextrins 3-functionalized with 8-hydroxyquinolines: copper-binding ability and inhibition of synuclein aggregation","volume":"11","author":"Oliveri","year":"2016","journal-title":"Chemistry\u2013An Asian Journal"},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib45","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1039\/c1mt00106j","article-title":"Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases","volume":"3","author":"Breydo","year":"2011","journal-title":"Metallomics"},{"issue":"30","key":"10.1016\/j.ejmech.2019.01.045_bib46","doi-asserted-by":"crossref","first-page":"9893","DOI":"10.1021\/ja0618649","article-title":"Interaction of \u03b1-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement","volume":"128","author":"Binolfi","year":"2006","journal-title":"J.\u00a0Am. Chem. Soc."},{"issue":"22","key":"10.1016\/j.ejmech.2019.01.045_bib47","doi-asserted-by":"crossref","first-page":"10668","DOI":"10.1021\/ic1016752","article-title":"Bioinorganic chemistry of Parkinson's disease: structural determinants for the copper-mediated amyloid formation of alpha-synuclein","volume":"49","author":"Binolfi","year":"2010","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2019.01.045_bib48","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jinorgbio.2016.04.012","article-title":"Coordination and redox properties of copper interaction with \u03b1-synuclein","volume":"163","author":"Valensin","year":"2016","journal-title":"J.\u00a0Inorg. Biochem."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1039\/C4MT00339J","article-title":"Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease","volume":"7","author":"Carboni","year":"2015","journal-title":"Metallomics"},{"issue":"9","key":"10.1016\/j.ejmech.2019.01.045_bib50","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1021\/acschemneuro.6b00175","article-title":"Natural tripeptide-based inhibitor of multifaceted amyloid \u03b2 toxicity","volume":"7","author":"Rajasekhar","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"36","key":"10.1016\/j.ejmech.2019.01.045_bib51","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1002\/ejic.201501198","article-title":"A\u00a08-hydroxyquinoline-cyclodextrin conjugate as an efficient chelating agent for cobalt (II) and nickel (II) in neutral aqueous solution","volume":"2015","author":"Sgarlata","year":"2015","journal-title":"Eur. J. Inorg. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib52","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00023210-200317100-00004","article-title":"Neuroprotective strategies in Parkinson's disease","volume":"17","author":"Mandel","year":"2003","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib53","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2174\/1570159X01666160930121647","article-title":"Recombinant antibody fragments for neurodegenerative diseases","volume":"15","author":"Manoutcharian","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"19","key":"10.1016\/j.ejmech.2019.01.045_bib54","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1021\/bi0600749","article-title":"Small molecule inhibitors of \u03b1-synuclein filament assembly","volume":"45","author":"Masuda","year":"2006","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib55","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body\u2013like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2019.01.045_bib56","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/mds.23012","article-title":"Characterization of Lewy body pathology in 12-and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease","volume":"25","author":"Li","year":"2010","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib57","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4103\/1673-5374.233432","article-title":"Natural polyphenols effects on protein aggregates in Alzheimer's and Parkinson's prion-like diseases","volume":"13","author":"Freyssin","year":"2018","journal-title":"Neural regeneration research"},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib58","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4155\/fmc-2017-0016","article-title":"\u03b1-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease","volume":"9","author":"Singh","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.045_bib59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.foodchem.2014.10.057","article-title":"Bioactivity of phenolic acids: metabolites versus parent compounds: a review","volume":"173","author":"Heleno","year":"2015","journal-title":"Food Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib60","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.3390\/molecules15117985","article-title":"Monocyclic phenolic acids; hydroxy-and polyhydroxybenzoic acids: occurrence and recent bioactivity studies","volume":"15","author":"Khadem","year":"2010","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib61","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.3390\/molecules15117792","article-title":"Nutraceutical antioxidants as novel neuroprotective agents","volume":"15","author":"Kelsey","year":"2010","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib62","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.abb.2010.03.016","article-title":"Caffeic acid, tyrosol and p-coumaric acid are potent inhibitors of 5-S-cysteinyl-dopamine induced neurotoxicity","volume":"501","author":"Vauzour","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1471-4159.2006.03707.x","article-title":"Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for \u03b1-synuclein fibrils in\u00a0vitro","volume":"97","author":"Ono","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2019.01.045_bib64","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.biochi.2014.11.011","article-title":"Anti-fibrillation potency of caffeic acid against an antidepressant induced fibrillogenesis of human \u03b1-synuclein: implications for Parkinson's disease","volume":"108","author":"Fazili","year":"2015","journal-title":"Biochimie"},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib65","first-page":"197","article-title":"Structure activity relationship of phenolic acid inhibitors of \u03b1-synuclein fibril formation and toxicity","volume":"5","author":"Ardah","year":"2014","journal-title":"Front. Aging Neurosci."},{"issue":"41","key":"10.1016\/j.ejmech.2019.01.045_bib66","doi-asserted-by":"crossref","first-page":"7722","DOI":"10.1021\/acs.jafc.6b03217","article-title":"Protocatechuic acid: inhibition of fibril formation, destabilization of preformed fibrils of amyloid-\u03b2 and \u03b1-synuclein, and neuroprotection","volume":"64","author":"Hornedo-Ortega","year":"2016","journal-title":"J.\u00a0Agric. Food Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2019.01.045_bib67","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.1074\/jbc.M109.080390","article-title":"Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of \u03b1-synuclein and \u03b2-amyloid and protect against amyloid-induced toxicity","volume":"285","author":"Di Giovanni","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2019.01.045_bib68","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.bbapap.2014.04.013","article-title":"Gallic acid interacts with \u03b1-synuclein to prevent the structural collapse necessary for its aggregation","volume":"1844","author":"Liu","year":"2014","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"key":"10.1016\/j.ejmech.2019.01.045_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2018.06.059","article-title":"Protective effects of hydroxytyrosol against \u03b1-synuclein toxicity on PC12 cells and fibril formation","volume":"120","author":"Hornedo-Ortega","year":"2018","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejmech.2019.01.045_bib70","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.taap.2016.04.009","article-title":"Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases","volume":"301","author":"Lv","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib71","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bbadis.2005.11.009","article-title":"A\u00a0yeast-based model of \u03b1-synucleinopathy identifies compounds with therapeutic potential","volume":"1762","author":"Griffioen","year":"2006","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2019.01.045_bib72","series-title":"Effects of Various Flavonoids on The-Synuclein Fibrillation Process","author":"Meng","year":"2010"},{"issue":"8","key":"10.1016\/j.ejmech.2019.01.045_bib73","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.febslet.2011.03.046","article-title":"Inhibition and disaggregation of \u00e1-synuclein oligomers by natural polyphenolic compounds","volume":"585","author":"Caruana","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2019.01.045_bib74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fchem.2018.00181","article-title":"Exploring the structural diversity in inhibitors of \u03b1-synuclein amyloidogenic folding, aggregation and neurotoxicity","volume":"6","author":"Das","year":"2018","journal-title":"Front. Chem."},{"issue":"34","key":"10.1016\/j.ejmech.2019.01.045_bib75","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1021\/bi900506b","article-title":"Molecular mechanisms underlying the flavonoid-induced inhibition of \u03b1-synuclein fibrillation","volume":"48","author":"Meng","year":"2009","journal-title":"Biochemistry"},{"issue":"26","key":"10.1016\/j.ejmech.2019.01.045_bib76","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1074\/jbc.M403129200","article-title":"The flavonoid baicalein inhibits fibrillation of \u03b1-synuclein and disaggregates existing fibrils","volume":"279","author":"Zhu","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib77","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jmb.2008.08.039","article-title":"Structural characteristics of \u03b1-synuclein oligomers stabilized by the flavonoid baicalein","volume":"383","author":"Hong","year":"2008","journal-title":"J.\u00a0Mol. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib78","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/cbic.201000604","article-title":"Baicalein inhibits formation of \u03b1-synuclein oligomers within living cells and prevents A\u03b2 peptide fibrillation and oligomerisation","volume":"12","author":"Lu","year":"2011","journal-title":"Chembiochem"},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/07391102.2003.10506918","article-title":"A\u00a0protein-chameleon: conformational plasticity of \u03b1-synuclein, a disordered protein involved in neurodegenerative disorders","volume":"21","author":"Uversky","year":"2003","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"issue":"16","key":"10.1016\/j.ejmech.2019.01.045_bib80","doi-asserted-by":"crossref","first-page":"10992","DOI":"10.1074\/jbc.M709634200","article-title":"Single particle characterization of iron-induced pore-forming \u03b1-synuclein oligomers","volume":"283","author":"Kostka","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib81","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.pbb.2009.03.008","article-title":"Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in\u00a0vivo and in\u00a0vitro","volume":"92","author":"Mu","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib82","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neulet.2008.05.116","article-title":"Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile","volume":"441","author":"Cheng","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"8","key":"10.1016\/j.ejmech.2019.01.045_bib83","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/sj.bjp.0704959","article-title":"The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study","volume":"137","author":"Tsai","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib84","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijpharm.2006.01.011","article-title":"Preparation, characterization and in\u00a0vivo evaluation of formulation of baicalein with hydroxypropyl-\u03b2-cyclodextrin","volume":"312","author":"Liu","year":"2006","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib85","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1208\/s12248-011-9277-6","article-title":"Hepatic metabolism and disposition of baicalein via the coupling of conjugation enzymes and transporters\u2014in\u00a0vitro and in\u00a0vivo evidences","volume":"13","author":"Zhang","year":"2011","journal-title":"AAPS J."},{"issue":"3\u20134","key":"10.1016\/j.ejmech.2019.01.045_bib86","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejps.2007.04.001","article-title":"Mechanistic study on the intestinal absorption and disposition of baicalein","volume":"31","author":"Zhang","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib87","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.bbagen.2012.12.027","article-title":"Oxidized quercetin inhibits \u03b1-synuclein fibrillization","volume":"1830","author":"Zhu","year":"2013","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib88","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2478\/s11658-010-0006-4","article-title":"Flavonoid transport across RBE4 cells: a blood-brain barrier model","volume":"15","author":"Faria","year":"2010","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib89","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1016\/j.bbagen.2013.06.029","article-title":"Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases","volume":"1830","author":"Cheng","year":"2013","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib90","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"52","key":"10.1016\/j.ejmech.2019.01.045_bib91","doi-asserted-by":"crossref","first-page":"32508","DOI":"10.1039\/C7RA03752J","article-title":"(\u2212)-Epigallocatechin-3-gallate (EGCG) inhibits fibrillation, disaggregates amyloid fibrils of \u03b1-synuclein, and protects PC12 cells against \u03b1-synuclein-induced toxicity","volume":"7","author":"Zhao","year":"2017","journal-title":"RSC Adv."},{"issue":"17","key":"10.1016\/j.ejmech.2019.01.045_bib92","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/acs.analchem.6b00731","article-title":"Opposite structural effects of epigallocatechin-3-gallate and dopamine binding to \u03b1-synuclein","volume":"88","author":"Konijnenberg","year":"2016","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib93","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1071\/CH10334","article-title":"Ion mobility mass spectrometry studies of the inhibition of alpha synuclein amyloid fibril formation by (\u2013)-Epigallocatechin-3-Gallate","volume":"64","author":"Liu","year":"2011","journal-title":"Aust. J. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2019.01.045_bib94","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","article-title":"Green tea (\u2212)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models","volume":"15","author":"Ehrnhoefer","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"31","key":"10.1016\/j.ejmech.2019.01.045_bib95","doi-asserted-by":"crossref","first-page":"21299","DOI":"10.1074\/jbc.M114.554667","article-title":"How epigallocatechin gallate can inhibit \u03b1-synuclein oligomer toxicity in\u00a0vitro","volume":"289","author":"Lorenzen","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib96","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1038\/s41598-017-18349-z","article-title":"EGCG-mediated protection of the membrane disruption and cytotoxicity caused by the \u2018active oligomer\u2019of \u03b1-synuclein","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.ejmech.2019.01.045_bib97","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","article-title":"EGCG remodels mature \u03b1-synuclein and amyloid-\u03b2 fibrils and reduces cellular toxicity","volume":"107","author":"Bieschke","year":"2010","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib98","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/cbdd.13067","article-title":"Influence of Egcg on \u03b1-synuclein (\u03b1s) aggregation and identification of their possible binding mode: a computational study using molecular dynamics simulation","volume":"91","author":"Liu","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"issue":"20","key":"10.1016\/j.ejmech.2019.01.045_bib99","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1021\/ja3115696","article-title":"Toward the molecular mechanism (s) by which EGCG treatment remodels mature amyloid fibrils","volume":"135","author":"Palhano","year":"2013","journal-title":"J.\u00a0Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib100","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/carcin\/19.10.1771","article-title":"Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue","volume":"19","author":"Suganuma","year":"1998","journal-title":"Carcinogenesis"},{"issue":"9","key":"10.1016\/j.ejmech.2019.01.045_bib101","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.3390\/ijms12095592","article-title":"Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises?","volume":"12","author":"Mereles","year":"2011","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib102","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/nu8060367","article-title":"Piceatannol and other wine stilbenes: a pool of inhibitors against \u03b1-synuclein aggregation and cytotoxicity","volume":"8","author":"Temsamani","year":"2016","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib103","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1139\/cjpp-2016-0209","article-title":"Tetrahydroxystilbene glucoside inhibits \u03b1-synuclein aggregation and apoptosis in A53T \u03b1-synuclein-transfected cells exposed to MPP+","volume":"95","author":"Zhang","year":"2017","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib104","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/open.201500155","article-title":"New glycoconjugates for the treatment of diseases related to metal dyshomeostasis","volume":"4","author":"Oliveri","year":"2015","journal-title":"ChemistryOpen"},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib105","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1039\/C2DT32429F","article-title":"Glycosylated copper (II) ionophores as prodrugs for \u03b2-glucosidase activation in targeted cancer therapy","volume":"42","author":"Oliveri","year":"2013","journal-title":"Dalton Trans."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib106","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1440-1681.2011.05648.x","article-title":"Discovery of curcumin, a component of golden spice, and its miraculous biological activities","volume":"39","author":"Gupta","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib107","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1474-4422(02)00105-9","article-title":"Experiences of Parkinson's disease in India","volume":"1","author":"Behari","year":"2002","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.ejmech.2019.01.045_bib108","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/mds.10449","article-title":"Lower risk of Parkinson's disease in an admixed population of European and Indian origins","volume":"18","author":"Ragothaman","year":"2003","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/138161212798918995","article-title":"Curcumin: a potential neuroprotective agent in Parkinson's disease","volume":"18","author":"Mythri","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib110","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/10715760500233113","article-title":"Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease","volume":"39","author":"Zbarsky","year":"2005","journal-title":"Free Radic. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib111","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2202-11-57","article-title":"Curcumin reduces \u03b1-synuclein induced cytotoxicity in Parkinson's disease cell model","volume":"11","author":"Wang","year":"2010","journal-title":"BMC Neurosci."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib112","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10787-007-1614-0","article-title":"Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice","volume":"16","author":"Rajeswari","year":"2008","journal-title":"Inflammopharmacology"},{"issue":"12","key":"10.1016\/j.ejmech.2019.01.045_bib113","doi-asserted-by":"crossref","first-page":"9193","DOI":"10.1074\/jbc.M111.325548","article-title":"Curcumin prevents aggregation in \u03b1-synuclein by increasing reconfiguration rate","volume":"287","author":"Ahmad","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib114","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/cn3001203","article-title":"Curcumin modulates \u03b1-synuclein aggregation and toxicity","volume":"4","author":"Singh","year":"2012","journal-title":"ACS Chem. Neurosci."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib115","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00401-007-0332-4","article-title":"Curcumin inhibits aggregation of \u03b1-synuclein","volume":"115","author":"Pandey","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejmech.2019.01.045_bib116","doi-asserted-by":"crossref","first-page":"28511","DOI":"10.1038\/srep28511","article-title":"Effect of curcumin analogs on\u03b1-synuclein aggregation and cytotoxicity","volume":"6","author":"Jha","year":"2016","journal-title":"Sci. Rep."},{"issue":"25","key":"10.1016\/j.ejmech.2019.01.045_bib117","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1021\/bi500642f","article-title":"\u03b2-cyclodextrin and curcumin, a potent cocktail for disaggregating and\/or inhibiting amyloids: a case study with \u03b1-synuclein","volume":"53","author":"Gautam","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.01.045_bib118","doi-asserted-by":"crossref","first-page":"9862","DOI":"10.1038\/srep09862","article-title":"Curcumin pyrazole and its derivative (N-(3-Nitrophenylpyrazole) curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of wild type and mutant \u03b1-synuclein","volume":"5","author":"Ahsan","year":"2015","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.ejmech.2019.01.045_bib119","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0731-7085(96)02024-9","article-title":"Stability of curcumin in buffer solutions and characterization of its degradation products","volume":"15","author":"Wang","year":"1997","journal-title":"J.\u00a0Pharmaceut. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4143\/crt.2014.46.1.2","article-title":"Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice","volume":"46","author":"Prasad","year":"2014","journal-title":"Canc. Res. Treat.: Off. J. Kor. Canc. Assoc."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib121","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00726-013-1503-3","article-title":"Small molecules interacting with \u03b1-synuclein: antiaggregating and cytoprotective properties","volume":"45","author":"Marchiani","year":"2013","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib122","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/138161212798919093","article-title":"Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits \u03b1-synuclein oligomer formation: relevance to Parkinson's disease","volume":"18","author":"Shrikanth Gadad","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"issue":"15","key":"10.1016\/j.ejmech.2019.01.045_bib123","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2174\/1389557516666160505115634","article-title":"Glycoconjugates of quinolines: application in medicinal chemistry","volume":"16","author":"Oliveri","year":"2016","journal-title":"Mini Rev. Med. Chem."},{"issue":"40","key":"10.1016\/j.ejmech.2019.01.045_bib124","doi-asserted-by":"crossref","first-page":"14047","DOI":"10.1002\/chem.201502155","article-title":"Unusual cyclodextrin derivatives as a new avenue to modulate self-and metal-induced A\u03b2 aggregation","volume":"21","author":"Oliveri","year":"2015","journal-title":"Chemistry\u2013A European Journal"},{"issue":"53","key":"10.1016\/j.ejmech.2019.01.045_bib125","doi-asserted-by":"crossref","first-page":"47229","DOI":"10.1039\/C6RA04204J","article-title":"Trehalose-8-hydroxyquinoline conjugates as antioxidant modulators of A\u03b2 aggregation","volume":"6","author":"Oliveri","year":"2016","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib126","first-page":"655","article-title":"Structural isomers of cyclodextrin-bearing IOX1 compound as inhibitors of A\u03b2 aggregation","volume":"2","author":"Oliveri","year":"2017","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2019.01.045_bib127","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jinorgbio.2016.05.012","article-title":"Prochelator strategies for site-selective activation of metal chelators","volume":"162","author":"Oliveri","year":"2016","journal-title":"J.\u00a0Inorg. Biochem."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2019.01.045_bib128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0378-5173(02)00323-X","article-title":"Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability","volume":"244","author":"T\u00f8nnesen","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib129","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/asia.201600259","article-title":"Cyclodextrins as protective agents of protein aggregation: an overview","volume":"11","author":"Oliveri","year":"2016","journal-title":"Chemistry\u2013An Asian Journal"},{"issue":"18","key":"10.1016\/j.ejmech.2019.01.045_bib130","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1002\/chem.201700031","article-title":"Cyclodextrin nanoparticles bearing 8-hydroxyquinoline ligands as multifunctional biomaterials","volume":"23","author":"Oliveri","year":"2017","journal-title":"Chemistry-A European Journal"},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib131","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbapap.2017.02.014","article-title":"Polyphenols in combination with \u03b2-cyclodextrin can inhibit and disaggregate \u03b1-synuclein amyloids under cell mimicking conditions: a promising therapeutic alternative","volume":"1865","author":"Gautam","year":"2017","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib132","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/nn.4660","article-title":"Synuclein and dopamine: the bonnie and clyde of Parkinson's disease","volume":"20","author":"Roy","year":"2017","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib133","first-page":"777","article-title":"Dopamine-modified \u03b1-synuclein blocks chaperone-mediated autophagy","volume":"118","author":"Martinez-Vicente","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib134","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/nn.4641","article-title":"Dopamine induces soluble \u03b1-synuclein oligomers and nigrostriatal degeneration","volume":"20","author":"Mor","year":"2017","journal-title":"Nat. Neurosci."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib135","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1096\/fj.04-3437fje","article-title":"Dopamine promotes \u03b1-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway","volume":"19","author":"Cappai","year":"2005","journal-title":"FASEB J."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib136","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s11064-009-9986-8","article-title":"Modulation of \u03b1-synuclein aggregation by dopamine: a review","volume":"34","author":"Leong","year":"2009","journal-title":"Neurochem. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib137","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbrc.2010.03.044","article-title":"Dopamine quinones interact with \u03b1-synuclein to form unstructured adducts","volume":"394","author":"Bisaglia","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.ejmech.2019.01.045_bib138","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1007\/s13361-013-0676-z","article-title":"Binding of dopamine to alpha-synuclein is mediated by specific conformational states","volume":"24","author":"Illes-Toth","year":"2013","journal-title":"J.\u00a0Am. Soc. Mass Spectrom."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib139","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jmb.2009.03.053","article-title":"At low concentrations, 3, 4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to \u03b1-synuclein and prevents its fibrillation","volume":"388","author":"Zhou","year":"2009","journal-title":"J.\u00a0Mol. Biol."},{"issue":"5545","key":"10.1016\/j.ejmech.2019.01.045_bib140","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.1063522","article-title":"Kinetic stabilization of the \u03b1-synuclein protofibril by a dopamine-\u03b1-synuclein adduct","volume":"294","author":"Conway","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.01.045_bib141","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M115.686584","article-title":"Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of alpha-synuclein with the toxic dopamine metabolite 3, 4-dihydroxyphenylacetaldehyde (DOPAL)","author":"Follmer","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2019.01.045_bib142","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1111\/j.1742-4658.2005.04792.x","article-title":"Inhibition of \u03b1-synuclein fibrillization by dopamine analogs via reaction with the amino groups of \u03b1-synuclein: implication for dopaminergic neurodegeneration","volume":"272","author":"Li","year":"2005","journal-title":"FEBS J."},{"issue":"21","key":"10.1016\/j.ejmech.2019.01.045_bib143","doi-asserted-by":"crossref","first-page":"15597","DOI":"10.1074\/jbc.M610893200","article-title":"Kinetic and structural analysis of the early oxidation products of dopamine analysis of the interactions with \u03b1-synuclein","volume":"282","author":"Bisaglia","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2019.01.045_bib144","doi-asserted-by":"crossref","first-page":"21212","DOI":"10.1074\/jbc.M412621200","article-title":"Reversible inhibition of \u03b1-synuclein fibrillization by dopaminochrome-mediated conformational alterations","volume":"280","author":"Norris","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib145","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.freeradbiomed.2009.02.009","article-title":"Formation of dopamine-mediated \u03b1-synuclein-soluble oligomers requires methionine oxidation","volume":"46","author":"Leong","year":"2009","journal-title":"Free Radic. Biol. Med."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2019.01.045_bib146","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-5793(02)02638-8","article-title":"Methionine oxidation inhibits fibrillation of human \u03b1-synuclein in\u00a0vitro","volume":"517","author":"Uversky","year":"2002","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib147","doi-asserted-by":"crossref","first-page":"e9234","DOI":"10.1371\/journal.pone.0009234","article-title":"Modulation of alpha-synuclein aggregation by dopamine analogs","volume":"5","author":"Latawiec","year":"2010","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003394","article-title":"Inhibition of \u03b1-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region","volume":"3","author":"Herrera","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.01.045_bib149","first-page":"149","article-title":"Demonstration of three dopamine molecules bound to \u03b1-synuclein: implication of oligomerization at the initial stage","volume":"3","author":"Shimotakahara","year":"2012","journal-title":"J.\u00a0Biophys. Chem."},{"issue":"43","key":"10.1016\/j.ejmech.2019.01.045_bib150","doi-asserted-by":"crossref","first-page":"31621","DOI":"10.1074\/jbc.M704737200","article-title":"Cellular oligomerization of \u03b1-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence","volume":"282","author":"Mazzulli","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"issue":"38","key":"10.1016\/j.ejmech.2019.01.045_bib151","doi-asserted-by":"crossref","first-page":"6672","DOI":"10.1021\/bi400367r","article-title":"A\u00a0molecular dynamics simulation-based interpretation of nuclear magnetic resonance multidimensional heteronuclear spectra of \u03b1-synuclein\u00b7dopamine adducts","volume":"52","author":"Dibenedetto","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.01.045_bib152","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1038\/srep05366","article-title":"Atomic force microscopy based nanoassay: a new method to study \u03b1-Synuclein-dopamine bioaffinity interactions","volume":"4","author":"Corvaglia","year":"2014","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib153","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/pro.2521","article-title":"Dopamine-induced \u03b1-synuclein oligomers show self-and cross-propagation properties","volume":"23","author":"Planchard","year":"2014","journal-title":"Protein Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2019.01.045_bib154","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s11064-015-1597-y","article-title":"Stabilization of alpha-synuclein oligomers in\u00a0vitro by the neurotransmitters, dopamine and norepinephrine: the effect of oxidized catecholamines","volume":"40","author":"Fischer","year":"2015","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejmech.2019.01.045_bib155","doi-asserted-by":"crossref","first-page":"24526","DOI":"10.1038\/srep24526","article-title":"Structural and functional properties of prefibrillar \u03b1-synuclein oligomers","volume":"6","author":"Pieri","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib156","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.bbrc.2006.08.144","article-title":"Pyrroloquinoline quinone (PQQ) prevents fibril formation of \u03b1-synuclein","volume":"349","author":"Kobayashi","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib157","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1326-5-20","article-title":"The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein","volume":"5","author":"Kim","year":"2010","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejmech.2019.01.045_bib158","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1874070700903010040","article-title":"The inhibition of amyloid fibrillation using the proteolytic products of PQQ-modified \u03b1-synuclein","volume":"3","author":"Kobayashi","year":"2009","journal-title":"Open Biotechnol. J."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib159","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuint.2012.10.001","article-title":"Vitamins K interact with N-terminus \u03b1-synuclein and modulate the protein fibrillization in\u00a0vitro. Exploring the interaction between quinones and \u03b1-synuclein","volume":"62","author":"da Silva","year":"2013","journal-title":"Neurochem. Int."},{"issue":"24","key":"10.1016\/j.ejmech.2019.01.045_bib160","doi-asserted-by":"crossref","first-page":"7416","DOI":"10.1016\/j.bmc.2011.10.049","article-title":"Molecular insights into human monoamine oxidase (MAO) inhibition by 1, 4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO","volume":"19","author":"Cerqueira","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib161","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1079\/BJN19940043","article-title":"Vitamin K distribution in rat tissues: dietary phylloquinone is a source of tissue menaquinone-4","volume":"72","author":"Thijssen","year":"1994","journal-title":"Br. J. Nutr."},{"issue":"13","key":"10.1016\/j.ejmech.2019.01.045_bib162","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/WNR.0b013e32830b3661","article-title":"Rifampicin reduces \u03b1-synuclein in a transgenic mouse model of multiple system atrophy","volume":"19","author":"Ubhi","year":"2008","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib163","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nan.12304","article-title":"Multiple system atrophy: emerging targets for interventional therapies","volume":"42","author":"Stefanova","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib164","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(13)70301-6","article-title":"Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial","volume":"13","author":"Low","year":"2014","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib165","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","article-title":"Rifampicin inhibits \u03b1-synuclein fibrillation and disaggregates fibrils","volume":"11","author":"Li","year":"2004","journal-title":"Chem. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib166","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10072-012-1156-0","article-title":"Rifampicin and Parkinson's disease","volume":"34","author":"Bi","year":"2013","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib167","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nchembio.719","article-title":"Small-molecule conversion of toxic oligomers to nontoxic \u03b2-sheet\u2013rich amyloid fibrils","volume":"8","author":"Bieschke","year":"2012","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib168","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acs.biochem.5b01168","article-title":"Stabilization of \u03b1-synuclein fibril clusters prevents fragmentation and reduces seeding activity and toxicity","volume":"55","author":"Lam","year":"2016","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib169","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s13311-013-0192-7","article-title":"Natural compounds may open new routes to treatment of amyloid diseases","volume":"10","author":"Bieschke","year":"2013","journal-title":"Neurotherapeutics"},{"issue":"35","key":"10.1016\/j.ejmech.2019.01.045_bib170","doi-asserted-by":"crossref","first-page":"8322","DOI":"10.1021\/bi901285x","article-title":"On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of \u03b1-synuclein with Congo red and lacmoid","volume":"48","author":"Lendel","year":"2009","journal-title":"Biochemistry"},{"issue":"24","key":"10.1016\/j.ejmech.2019.01.045_bib171","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1074\/jbc.M112.434787","article-title":"A\u00a0blood-brain barrier (BBB) disrupter is also a potent \u03b1-synuclein (\u03b1-syn) aggregation inhibitor a novel dual mechanism of mannitol for the treatment of Parkinson diasease (PD)","volume":"288","author":"Shaltiel-Karyo","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib172","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbrc.2015.12.043","article-title":"\u03b1-Synuclein aggregation, seeding and inhibition by scyllo-inositol","volume":"469","author":"Ibrahim","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib173","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1471-4159.2009.06054.x","article-title":"Inducible over-expression of wild type \u03b1-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death","volume":"109","author":"Vekrellis","year":"2009","journal-title":"J.\u00a0Neurochem."},{"issue":"22","key":"10.1016\/j.ejmech.2019.01.045_bib174","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.1021\/jp311350r","article-title":"Binding mechanism of inositol stereoisomers to monomers and aggregates of A\u03b2 (16-22)","volume":"117","author":"Li","year":"2013","journal-title":"J.\u00a0Phys. Chem. B"},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib175","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/anie.200802621","article-title":"Development of tau aggregation inhibitors for Alzheimer's disease","volume":"48","author":"Bulic","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib176","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-5793(97)01290-8","article-title":"Hemin and related porphyrins inhibit \u03b2-amyloid aggregation","volume":"417","author":"Howlett","year":"1997","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib177","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1021\/acs.accounts.5b00507","article-title":"Phthalocyanines as molecular scaffolds to block disease-associated protein aggregation","volume":"49","author":"Valiente-Gabioud","year":"2016","journal-title":"Accounts Chem. Res."},{"issue":"37","key":"10.1016\/j.ejmech.2019.01.045_bib178","doi-asserted-by":"crossref","first-page":"32036","DOI":"10.1074\/jbc.M111.242958","article-title":"Toward the discovery of effective polycyclic inhibitors of \u03b1-synuclein amyloid assembly","volume":"286","author":"Lamberto","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2019.01.045_bib179","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1021\/bi0356707","article-title":"Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of \u03b1-synuclein","volume":"43","author":"Lee","year":"2004","journal-title":"Biochemistry"},{"issue":"50","key":"10.1016\/j.ejmech.2019.01.045_bib180","doi-asserted-by":"crossref","first-page":"21057","DOI":"10.1073\/pnas.0902603106","article-title":"Structural and mechanistic basis behind the inhibitory interaction of PcTS on \u03b1-synuclein amyloid fibril formation","volume":"106","author":"Lamberto","year":"2009","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"53","key":"10.1016\/j.ejmech.2019.01.045_bib181","doi-asserted-by":"crossref","first-page":"13010","DOI":"10.1002\/chem.201703001","article-title":"Small molecule-induced soluble oligomers of \u03b1-synuclein with helical structure","volume":"23","author":"Fonseca-Ornelas","year":"2017","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.ejmech.2019.01.045_bib182","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1038\/ncomms6857","article-title":"Small molecule-mediated stabilization of vesicle-associated helical \u03b1-synuclein inhibits pathogenic misfolding and aggregation","volume":"5","author":"Fonseca-Ornelas","year":"2014","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.ejmech.2019.01.045_bib183","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ccr.2012.05.004","article-title":"Bioinorganic chemistry of copper coordination to alpha-synuclein: relevance to Parkinson's disease","volume":"256","author":"Binolfi","year":"2012","journal-title":"Coord. Chem. Rev."},{"issue":"16","key":"10.1016\/j.ejmech.2019.01.045_bib184","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1021\/bi8002378","article-title":"Characterization of \u03b1-synuclein interactions with selected aggregation-inhibiting small molecules","volume":"47","author":"Rao","year":"2008","journal-title":"Biochemistry"},{"issue":"39","key":"10.1016\/j.ejmech.2019.01.045_bib185","doi-asserted-by":"crossref","first-page":"11472","DOI":"10.1002\/anie.201504310","article-title":"Photoexcited porphyrins as a strong suppressor of \u03b2-amyloid aggregation and synaptic toxicity","volume":"54","author":"Lee","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"issue":"24","key":"10.1016\/j.ejmech.2019.01.045_bib186","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1002\/chem.201800807","article-title":"Porphyrin cyclodextrin conjugates modulate amyloid beta peptide aggregation and cytotoxicity","volume":"24","author":"Oliveri","year":"2018","journal-title":"Chem.\u2013Eur. J."},{"issue":"28","key":"10.1016\/j.ejmech.2019.01.045_bib187","first-page":"9122","article-title":"A\u00a0metalloporphyrin-peptide conjugate as an effective inhibitor of amyloid-\u03b2 peptide fibrillation and cytotoxicity","volume":"2","author":"Villari","year":"2017","journal-title":"Chemistry"},{"issue":"30","key":"10.1016\/j.ejmech.2019.01.045_bib188","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1021\/acs.biochem.5b00280","article-title":"Heme stabilization of \u03b1-Synuclein oligomers during amyloid fibril formation","volume":"54","author":"Hayden","year":"2015","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib189","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbrc.2014.10.062","article-title":"Hemin as a generic and potent protein misfolding inhibitor","volume":"454","author":"Liu","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib190","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.nbd.2006.10.010","article-title":"Vitamin A potently destabilizes preformed \u03b1-synuclein fibrils in\u00a0vitro: implications for Lewy body diseases","volume":"25","author":"Ono","year":"2007","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib191","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1021\/ic502713f","article-title":"Soluble sugar-based quinoline derivatives as new antioxidant modulators of metal-induced amyloid aggregation","volume":"54","author":"Oliveri","year":"2015","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2019.01.045_bib192","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nbd.2014.11.007","article-title":"Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils","volume":"74","author":"Ardah","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib193","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1568009054064642","article-title":"Squalamine: a polyvalent drug of the future?","volume":"5","author":"Brunel","year":"2005","journal-title":"Curr. Cancer Drug Targets"},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib194","doi-asserted-by":"crossref","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","article-title":"A\u00a0natural product inhibits the initiation of \u03b1-synuclein aggregation and suppresses its toxicity","volume":"114","author":"Perni","year":"2017","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"8","key":"10.1016\/j.ejmech.2019.01.045_bib195","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","article-title":"Multistep inhibition of \u03b1-synuclein aggregation and toxicity in\u00a0vitro and in\u00a0vivo by trodusquemine","volume":"13","author":"Perni","year":"2018","journal-title":"ACS Chem. Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2019.01.045_bib196","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.2337\/diabetes.51.7.2099","article-title":"Appetite suppression and weight reduction by a centrally active aminosterol","volume":"51","author":"Ahima","year":"2002","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib197","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jnnp.2003.020982","article-title":"Are men at greater risk for Parkinson's disease than women?","volume":"75","author":"Wooten","year":"2004","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib198","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/aje\/kwg068","article-title":"Incidence of Parkinson's disease: variation by age, gender, and race\/ethnicity","volume":"157","author":"Van Den Eeden","year":"2003","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib199","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archneur.61.6.886","article-title":"Postmenopausal estrogen use affects risk for Parkinson disease","volume":"61","author":"Currie","year":"2004","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib200","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.expneurol.2009.03.003","article-title":"Anti-aggregation and fibril-destabilizing effects of sex hormones on \u03b1-synuclein fibrils in\u00a0vitro","volume":"217","author":"Hirohata","year":"2009","journal-title":"Exp. Neurol."},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib201","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib202","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-014-1265-3","article-title":"The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset","volume":"127","author":"Levin","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejmech.2019.01.045_bib203","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2016.00099","article-title":"Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy","volume":"10","author":"Fellner","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2019.01.045_bib204","series-title":"Proceedings of the National Academy of Sciences","article-title":"Treatment with diphenyl\u2013pyrazole compound anle138b\/c reveals that \u03b1-synuclein protects melanoma cells from autophagic cell death","author":"Turriani","year":"2017"},{"issue":"9","key":"10.1016\/j.ejmech.2019.01.045_bib205","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.bbagen.2015.05.021","article-title":"Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to \u03b1-synuclein aggregates","volume":"1850","author":"Deeg","year":"2015","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib206","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1021\/cn200072h","article-title":"Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats","volume":"3","author":"Leung","year":"2011","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib207","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1021\/cn400149k","article-title":"Ceftriaxone blocks the polymerization of \u03b1-synuclein and exerts neuroprotective effects in\u00a0vitro","volume":"5","author":"Ruzza","year":"2013","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib208","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0922-4106(95)90013-6","article-title":"Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors","volume":"290","author":"Mierau","year":"1995","journal-title":"Eur. J. Pharmacol. Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib209","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0014-2999(01)00902-5","article-title":"Release and aggregation of cytochrome c and \u03b1-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole","volume":"417","author":"Kakimura","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.01.045_bib210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nbd.2017.07.007","article-title":"Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form","volume":"106","author":"Collier","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib211","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.bbapap.2008.09.026","article-title":"Smoking and Parkinson's disease: does nicotine affect \u03b1-synuclein fibrillation?","volume":"1794","author":"Hong","year":"2009","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib212","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.expneurol.2007.03.002","article-title":"Anti-fibrillogenic and fibril-destabilizing activity of nicotine in\u00a0vitro: implications for the prevention and therapeutics of Lewy body diseases","volume":"205","author":"Ono","year":"2007","journal-title":"Exp. Neurol."},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib213","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bbadis.2017.02.002","article-title":"Nicotine slows down oligomerisation of \u03b1-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease","volume":"1863","author":"Kardani","year":"2017","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2019.01.045_bib214","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2014.07.090","article-title":"The use of nanopore analysis for discovering drugs which bind to \u03b1-synuclein for treatment of Parkinson's disease","volume":"88","author":"Tavassoly","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2019.01.045_bib215","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1021\/acschemneuro.5b00158","article-title":"Understanding caffeine's role in attenuating the toxicity of \u03b1-synuclein aggregates: implications for risk of Parkinson's disease","volume":"6","author":"Kardani","year":"2015","journal-title":"ACS Chem. Neurosci."},{"issue":"7","key":"10.1016\/j.ejmech.2019.01.045_bib216","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/jnr.21271","article-title":"Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for \u03b1-synuclein fibrils in\u00a0vitro","volume":"85","author":"Ono","year":"2007","journal-title":"J.\u00a0Neurosci. Res."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib217","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/jnr.23256","article-title":"Effects of antiparkinsonian agents on \u03b2-amyloid and \u03b1-synuclein oligomer formation in\u00a0vitro","volume":"91","author":"Ono","year":"2013","journal-title":"J.\u00a0Neurosci. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2011.20.1.1","article-title":"MAO-inhibitors in Parkinson's disease","volume":"20","author":"Riederer","year":"2011","journal-title":"Exp. Neurobiol."},{"issue":"8","key":"10.1016\/j.ejmech.2019.01.045_bib219","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/01.wnl.0000204007.46190.54","article-title":"Selegiline slows the progression of the symptoms of Parkinson disease","volume":"66","author":"P\u00e5lhagen","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib220","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jmb.2010.10.027","article-title":"The anti-Parkinsonian drug selegiline delays the nucleation phase of \u03b1-synuclein aggregation leading to the formation of nontoxic species","volume":"405","author":"Braga","year":"2011","journal-title":"J.\u00a0Mol. Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2019.01.045_bib221","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1021\/cn200133x","article-title":"Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01","volume":"3","author":"Sinha","year":"2012","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib222","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s13311-012-0105-1","article-title":"A\u00a0novel \u201cmolecular tweezer\u201d inhibitor of \u03b1-synuclein neurotoxicity in\u00a0vitro and in\u00a0vivo","volume":"9","author":"Prabhudesai","year":"2012","journal-title":"Neurotherapeutics"},{"issue":"15","key":"10.1016\/j.ejmech.2019.01.045_bib223","doi-asserted-by":"crossref","first-page":"10727","DOI":"10.1074\/jbc.M113.524520","article-title":"Molecular basis for preventing \u03b1-synuclein aggregation by a molecular tweezer","volume":"289","author":"Acharya","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib224","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2050-6511-15-23","article-title":"Safety and pharmacological characterization of the molecular tweezer CLR01\u2013a broad-spectrum inhibitor of amyloid proteins' toxicity","volume":"15","author":"Attar","year":"2014","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib225","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijbiomac.2011.02.021","article-title":"PAMAM G4 dendrimers affect the aggregation of \u03b1-synuclein","volume":"48","author":"Milowska","year":"2011","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib226","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/mabi.200800242","article-title":"PAMAM dendrimers as potential agents against fibrillation of \u03b1-synuclein, a Parkinson's disease-related protein","volume":"9","author":"Rekas","year":"2009","journal-title":"Macromol. Biosci."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib227","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.ijbiomac.2012.02.003","article-title":"Phosphorus-containing dendrimers against \u03b1-synuclein fibril formation","volume":"50","author":"Milowska","year":"2012","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib228","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/mp300636h","article-title":"Viologen-phosphorus dendrimers inhibit \u03b1-synuclein fibrillation","volume":"10","author":"Milowska","year":"2013","journal-title":"Mol. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2019.01.045_bib229","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijpharm.2015.02.066","article-title":"Carbosilane dendrimers inhibit \u03b1-synuclein fibrillation and prevent cells from rotenone-induced damage","volume":"484","author":"Milowska","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib230","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10529-010-0200-5","article-title":"Screening of DNA aptamer which binds to \u03b1-synuclein","volume":"32","author":"Tsukakoshi","year":"2010","journal-title":"Biotechnol. Lett."},{"issue":"13","key":"10.1016\/j.ejmech.2019.01.045_bib231","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1021\/ac300330g","article-title":"Selection of DNA aptamers that recognize \u03b1-synuclein oligomers using a competitive screening method","volume":"84","author":"Tsukakoshi","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2019.01.045_bib232","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.omtn.2018.02.011","article-title":"Novel DNA aptamers for Parkinson's disease treatment inhibit \u03b1-synuclein aggregation and facilitate its degradation","volume":"11","author":"Zheng","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"2\u20133","key":"10.1016\/j.ejmech.2019.01.045_bib233","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.ddtec.2009.01.002","article-title":"Intracellular delivery of protein and peptide therapeutics","volume":"5","author":"Torchilin","year":"2008","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2019.01.045_bib234","series-title":"Peptides for Youth","first-page":"467","article-title":"Opportunities and challenges of developing peptide drugs in the pharmaceutical industry","author":"Danho","year":"2009"},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib235","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1096\/fj.03-1346fje","article-title":"A\u00a0strategy for designing inhibitors of \u03b1-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders","volume":"18","author":"El-Agnaf","year":"2004","journal-title":"FASEB J."},{"issue":"25","key":"10.1016\/j.ejmech.2019.01.045_bib236","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1021\/ja075356q","article-title":"Design of an N-methylated peptide inhibitor of \u03b1-synuclein aggregation guided by solid-state NMR \u00a7","volume":"130","author":"Madine","year":"2008","journal-title":"J.\u00a0Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib237","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbrc.2011.04.034","article-title":"The hexapeptide PGVTAV suppresses neurotoxicity of human \u03b1-synuclein aggregates","volume":"408","author":"Choi","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib238","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/1471-2105-8-451","article-title":"Peptide ligand screening of \u03b1-synuclein aggregation modulators by in silico panning","volume":"8","author":"Abe","year":"2007","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ejmech.2019.01.045_bib239","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.abb.2017.09.015","article-title":"The inhibitory effects of biomimetically designed peptides on \u03b1-synuclein aggregation","volume":"634","author":"Rezaeian","year":"2017","journal-title":"Arch. Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib240","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00221-006-0539-y","article-title":"Inhibitors of \u03b1-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders","volume":"173","author":"Amer","year":"2006","journal-title":"Exp. Brain Res."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib241","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41598-018-23718-3","article-title":"Small molecules attenuate the interplay between conformational fluctuations, early oligomerization and amyloidosis of alpha synuclein","volume":"8","author":"Ghosh","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib242","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neulet.2003.12.077","article-title":"Inhibition of fibril formation and toxicity of a fragment of \u03b1-synuclein by an N-methylated peptide analogue","volume":"359","author":"Bodles","year":"2004","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib243","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bbrc.2009.07.083","article-title":"\u03b2-Sheet-breaking peptides inhibit the fibrillation of human \u03b1-synuclein","volume":"387","author":"Kim","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2019.01.045_bib244","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M114.620484","article-title":"Intracellular screening of a peptide library to derive a potent peptide inhibitor of \u03b1-synuclein aggregation","author":"Cheruvara","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib245","doi-asserted-by":"crossref","first-page":"e13863","DOI":"10.1371\/journal.pone.0013863","article-title":"Inhibiting \u03b1-synuclein oligomerization by stable cell-penetrating \u03b2-synuclein fragments recovers phenotype of Parkinson's disease model flies","volume":"5","author":"Shaltiel-Karyo","year":"2010","journal-title":"PLoS One"},{"issue":"40","key":"10.1016\/j.ejmech.2019.01.045_bib246","doi-asserted-by":"crossref","first-page":"14236","DOI":"10.1002\/chem.201601830","article-title":"Self-assembled cyclic d, l-\u03b1-Peptides as generic conformational inhibitors of the \u03b1-synuclein aggregation and toxicity: in\u00a0vitro and mechanistic studies","volume":"22","author":"Chemerovski-Glikman","year":"2016","journal-title":"Chem.-A Eur. J."},{"issue":"38","key":"10.1016\/j.ejmech.2019.01.045_bib247","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.1021\/bi200760h","article-title":"Designed hairpin peptides interfere with amyloidogenesis pathways: fibril formation and cytotoxicity inhibition, interception of the preamyloid state","volume":"50","author":"Huggins","year":"2011","journal-title":"Biochemistry"},{"issue":"15","key":"10.1016\/j.ejmech.2019.01.045_bib248","doi-asserted-by":"crossref","first-page":"11577","DOI":"10.1039\/C5RA00325C","article-title":"Binding interactions of agents that alter \u03b1-synuclein aggregation","volume":"5","author":"Sivanesam","year":"2015","journal-title":"RSC Adv."},{"issue":"10","key":"10.1016\/j.ejmech.2019.01.045_bib249","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/prot.23152","article-title":"Inhibition of \u03b1-synuclein aggregation by small heat shock proteins","volume":"79","author":"Bruinsma","year":"2011","journal-title":"Proteins: Struct., Funct., Bioinformat."},{"key":"10.1016\/j.ejmech.2019.01.045_bib250","doi-asserted-by":"crossref","first-page":"42880","DOI":"10.1038\/srep42880","article-title":"Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization","volume":"7","author":"Bonito-Oliva","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib251","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jmb.2006.08.062","article-title":"Heat shock protein 70 inhibits \u03b1-synuclein fibril formation via interactions with diverse intermediates","volume":"364","author":"Huang","year":"2006","journal-title":"J.\u00a0Mol. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2019.01.045_bib252","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1046\/j.1471-4159.2002.01190.x","article-title":"TorsinA and heat shock proteins act as molecular chaperones: suppression of \u03b1-synuclein aggregation","volume":"83","author":"McLean","year":"2002","journal-title":"J.\u00a0Neurochem."},{"issue":"3","key":"10.1016\/j.ejmech.2019.01.045_bib253","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bbrc.2006.10.085","article-title":"Small heat shock proteins protect against \u03b1-synuclein-induced toxicity and aggregation","volume":"351","author":"Outeiro","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.ejmech.2019.01.045_bib254","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1371\/journal.pbio.0020362","article-title":"DJ-1 is a redox-dependent molecular chaperone that inhibits \u03b1-synuclein aggregate formation","volume":"2","author":"Shendelman","year":"2004","journal-title":"PLoS Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2019.01.045_bib255","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.bbadis.2014.06.024","article-title":"Preventing \u03b1-synuclein aggregation: the role of the small heat-shock molecular chaperone proteins","volume":"1842","author":"Cox","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"16","key":"10.1016\/j.ejmech.2019.01.045_bib256","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1002\/anie.201309001","article-title":"Sequestration of a \u03b2-hairpin for control of \u03b1-synuclein aggregation","volume":"53","author":"Mirecka","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"issue":"50","key":"10.1016\/j.ejmech.2019.01.045_bib257","doi-asserted-by":"crossref","first-page":"12781","DOI":"10.1021\/acs.jpcb.6b08485","article-title":"Uncovering the binding and specificity of \u03b2-wrapins for amyloid-\u03b2 and \u03b1-synuclein","volume":"120","author":"Orr","year":"2016","journal-title":"J.\u00a0Phys. Chem. B"},{"issue":"20","key":"10.1016\/j.ejmech.2019.01.045_bib258","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1002\/ange.201801071","article-title":"Inhibition of \u03b1-synuclein amyloid fibril elongation by blocking fibril ends","volume":"130","author":"Shvadchak","year":"2018","journal-title":"Angew. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2019.01.045_bib259","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1021\/acschemneuro.7b00261","article-title":"Comparison of \u03b1-synuclein fibril inhibition by four different amyloid inhibitors","volume":"8","author":"Jha","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"12","key":"10.1016\/j.ejmech.2019.01.045_bib260","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1021\/acschemneuro.5b00172","article-title":"Drugs that bind to \u03b1-synuclein: neuroprotective or neurotoxic?","volume":"6","author":"Kakish","year":"2015","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.ejmech.2019.01.045_bib261","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/cn5002914","article-title":"Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to \u03b1-synuclein","volume":"6","author":"Kakish","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"19","key":"10.1016\/j.ejmech.2019.01.045_bib262","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1016\/j.febslet.2012.06.040","article-title":"Methamphetamine binds to \u03b1-synuclein and causes a conformational change which can be detected by nanopore analysis","volume":"586","author":"Tavassoly","year":"2012","journal-title":"FEBS Lett."},{"issue":"12","key":"10.1016\/j.ejmech.2019.01.045_bib263","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/13543776.2018.1541234","article-title":"Bicyclic bis-heteroaryl derivatives as inhibitors of the \u03b1-synuclein protein: a patent evaluation of WO2018138088A1","volume":"28","author":"Joubert","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib264","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-018-0497-5","article-title":"Activating autophagy as a therapeutic strategy for Parkinson's disease","volume":"32","author":"Fowler","year":"2018","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.ejmech.2019.01.045_bib265","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.27414","article-title":"Targeted therapies for Parkinson's disease: from genetics to the clinic","volume":"33","author":"Sardi","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2019.01.045_bib266","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrd.2017.95","article-title":"Zeroing in on neurodegenerative \u03b1-synuclein","volume":"16","author":"Kingwell","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2019.01.045_bib267","doi-asserted-by":"crossref","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","article-title":"The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease","volume":"8","author":"Price","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2019.01.045_bib268","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","article-title":"Therapeutic approaches to target\u00a0alpha-synuclein pathology","volume":"298","author":"Brundin","year":"2017","journal-title":"Exp. Neurol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419300650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419300650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:48:51Z","timestamp":1759326531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419300650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":268,"alternative-id":["S0223523419300650"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.045","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward the discovery and development of effective modulators of \u03b1-synuclein amyloid aggregation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}